[go: up one dir, main page]

MX2020010194A - Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. - Google Patents

Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.

Info

Publication number
MX2020010194A
MX2020010194A MX2020010194A MX2020010194A MX2020010194A MX 2020010194 A MX2020010194 A MX 2020010194A MX 2020010194 A MX2020010194 A MX 2020010194A MX 2020010194 A MX2020010194 A MX 2020010194A MX 2020010194 A MX2020010194 A MX 2020010194A
Authority
MX
Mexico
Prior art keywords
diseases associated
activation
treatment
reducing agent
ammonia reducing
Prior art date
Application number
MX2020010194A
Other languages
English (en)
Inventor
Rajiv Jalan
Krista Rombouts
Fausto Andreola
Chiara Francesco De
Karen Louise Thomsen
MOOKERJEE Rajeshwar PROSAD
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of MX2020010194A publication Critical patent/MX2020010194A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente métodos para prevenir, tratar y retrasar el inicio o progreso de enfermedades asociadas con células estrelladas hepáticas (HSC), tal como una enfermedad de hígado graso no alcohólico (NAFLD), fibrosis, y cáncer de hígado, usando terapias reductoras de amoníaco.
MX2020010194A 2014-11-24 2017-05-22 Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas. MX2020010194A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462083814P 2014-11-24 2014-11-24

Publications (1)

Publication Number Publication Date
MX2020010194A true MX2020010194A (es) 2020-10-20

Family

ID=56074936

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006685A MX375838B (es) 2014-11-24 2015-11-23 Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.
MX2020010194A MX2020010194A (es) 2014-11-24 2017-05-22 Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006685A MX375838B (es) 2014-11-24 2015-11-23 Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activación de células estrelladas hepáticas.

Country Status (17)

Country Link
US (3) US10039735B2 (es)
EP (2) EP3685841A1 (es)
JP (2) JP6797117B2 (es)
KR (2) KR102487376B1 (es)
CN (2) CN107206021B (es)
AU (2) AU2015353703B2 (es)
BR (1) BR112017010761B1 (es)
CA (1) CA2968544A1 (es)
DK (1) DK3223829T3 (es)
EA (1) EA201790913A1 (es)
ES (1) ES2769000T3 (es)
IL (2) IL281349B (es)
MX (2) MX375838B (es)
NZ (1) NZ732632A (es)
SG (1) SG11201704011XA (es)
WO (1) WO2016085887A1 (es)
ZA (1) ZA201703779B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
CN107206021B (zh) 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
JP2017019726A (ja) * 2015-07-07 2017-01-26 佐々木食品工業株式会社 Ｅｌｏｖｌ６阻害、ＮＡＳＨの予防又は治療並びにインスリン抵抗性改善用組成物
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US11083702B2 (en) * 2016-04-19 2021-08-10 University of Pittsburgh—of the Commonwealth System of Higher Education Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism
US11015196B2 (en) * 2016-05-20 2021-05-25 The General Hospital Corporation Using microRNAs to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018170234A1 (en) * 2017-03-15 2018-09-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
JP7126520B2 (ja) * 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
US12359184B2 (en) 2017-05-24 2025-07-15 Thoeris Gmbh Use of glutamine synthetase for treating hyperammonemia
MA49906A (fr) 2017-08-14 2020-06-24 Axcella Health Inc Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
KR102101342B1 (ko) * 2018-09-14 2020-04-17 재단법인 대구경북첨단의료산업진흥재단 타제메토스타트 또는 이의 유도체를 유효성분으로 함유하는 비알콜성 지방간염의 예방 또는 치료용 약학적 조성물
US12414986B2 (en) * 2018-09-28 2025-09-16 Thoeris Gmbh Use of glutamine synthetase for treating fatty liver disease
US12396675B2 (en) 2019-05-09 2025-08-26 Amalive Limited Methods of assessing hepatic encephalopathy
WO2023223520A1 (ja) * 2022-05-19 2023-11-23 Ｉｓｍ株式会社 活性化肝星細胞に対する脱活性化誘導剤スクリーニング系
WO2024149252A1 (zh) * 2023-01-09 2024-07-18 上海石趣医药科技有限公司 磷酸镁物质、包含其的药物组合物及其用途
CN116173020A (zh) * 2023-01-29 2023-05-30 广西壮族自治区人民医院 钩藤碱在制备防治肝脂肪变性或脂肪肝的药物中应用

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (es) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
DE4020980C1 (es) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
US5840891A (en) 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
WO1997030167A1 (en) 1996-02-13 1997-08-21 The Trustees Of The University Of Pennsylvania Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
AU4778700A (en) 1999-05-21 2000-12-12 Takeda Chemical Industries Ltd. Liver function controlling agents
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
JPWO2002074302A1 (ja) 2001-03-15 2005-07-14 独立行政法人理化学研究所 肝機能障害改善用アミノ酸組成物
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
EP1541141A1 (en) 2002-08-30 2005-06-15 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CA2565840A1 (en) 2004-05-06 2005-11-17 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
JP5116479B2 (ja) 2004-11-26 2013-01-09 ユーシーエル ビジネス ピーエルシー オルニチンならびにフェニルアセテートまたはフェニルブチレートを含む、肝性脳症を治療するための組成物
GB0426141D0 (en) * 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
JPWO2007077995A1 (ja) 2006-01-05 2009-06-11 協和発酵バイオ株式会社 筋肉増量剤
CA2998344C (en) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) * 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
US20120157526A1 (en) 2009-06-08 2012-06-21 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
JP2011236160A (ja) * 2010-05-11 2011-11-24 Shinshu Univ 非アルコール性肝疾患治療薬
JP6087284B2 (ja) 2010-10-06 2017-03-01 オセラ セラピューティクス， インコーポレイテッド Ｌ−オルニチンフェニルアセテートを製造するための方法
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
CN107206021B (zh) * 2014-11-24 2021-09-03 Ucl商业有限公司 使用降氨疗法治疗与肝星状细胞激活相关的疾病
WO2016172112A1 (en) 2015-04-20 2016-10-27 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US10835506B2 (en) 2015-08-18 2020-11-17 Ocera Therapeutics, Inc. Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
HK1257679A1 (zh) 2015-09-25 2019-10-25 Ocera Therapeutics, Inc. 使用l-鸟苷酸与苯乙酸根和苯基丁酸根中至少一种的结合治疗和预防神经元细胞损失
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
JP2017535575A (ja) 2017-11-30
AU2015353703A1 (en) 2017-06-15
US20200206175A1 (en) 2020-07-02
HK1243651A1 (en) 2018-07-20
BR112017010761B1 (pt) 2022-10-18
KR20230018526A (ko) 2023-02-07
DK3223829T3 (da) 2020-02-10
US20170354627A1 (en) 2017-12-14
US20190070142A1 (en) 2019-03-07
MX375838B (es) 2025-03-06
JP7199400B2 (ja) 2023-01-05
EP3223829A1 (en) 2017-10-04
EP3223829B1 (en) 2019-10-23
MX2017006685A (es) 2018-01-15
AU2015353703B2 (en) 2021-04-01
IL252405A0 (en) 2017-07-31
BR112017010761A2 (pt) 2018-01-09
EA201790913A1 (ru) 2017-11-30
CN107206021B (zh) 2021-09-03
CA2968544A1 (en) 2016-06-02
ES2769000T3 (es) 2020-06-24
CN113633777A (zh) 2021-11-12
NZ732632A (en) 2021-07-30
EP3685841A1 (en) 2020-07-29
IL281349B (en) 2022-09-01
WO2016085887A1 (en) 2016-06-02
KR102487376B1 (ko) 2023-01-10
SG11201704011XA (en) 2017-06-29
US10525029B2 (en) 2020-01-07
KR20170095894A (ko) 2017-08-23
AU2021203938A1 (en) 2021-07-08
ZA201703779B (en) 2021-10-27
IL281349A (en) 2021-04-29
JP6797117B2 (ja) 2020-12-09
US10039735B2 (en) 2018-08-07
EP3223829A4 (en) 2018-04-25
CN107206021A (zh) 2017-09-26
US11040021B2 (en) 2021-06-22
IL252405B (en) 2021-03-25
JP2020169180A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12018502429A1 (en) Antibody molecules for cancer treatment
CL2018003316A1 (es) Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786)
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
BR112017006664A2 (pt) terapias de combinação
MX384490B (es) Agentes que inducen apoptosis para el tratamiento de cancer y enfermedades inmunitarias y autoinmunitarias.
MX378273B (es) Compuestos activos hacia bromodominios.
WO2016025635A3 (en) Combination therapy for treating cancer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
SG11201802915WA (en) Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
WO2016043874A3 (en) Combination therapy for treating cancer
IL257274B (en) Compositions and methods for treating cancers associated with etbr activation
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
IL254228B (en) Cell therapeutic agent for cancer treatment and combination therapy with same
LT3168214T (lt) Pakeisti 2-tiokso-imidazolidin-4-onai ir jų spiro analogai, aktyvi priešvėžinė sudedamoji dalis, farmacinė kompozicija, medicininis paruošimas, prostatos vėžio gydymo būdas